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Background: The purpose of this study was to assess the efficacy of transcranial direct current stimulation (tDCS)
on verbal memory function in patients with Alzheimer’s disease.
Methods: We conducted a randomized, placebo-controlled clinical trial in which tDCS was applied in six 30-minute
sessions for 10 days. tDCS was delivered to the left temporal cortex with 2-mA intensity. A total of 25 patients with
Alzheimer’s disease were enrolled in the study. All of the patients were diagnosed according to National Institute of
Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association
criteria. Twelve patients received active stimulation, and thirteen patients received placebo stimulation. The primary
outcome measure was the change in two parallel versions of the California Verbal Learning Test–Second Edition,
a standardized neuropsychological memory test normalized by age and gender. The secondary outcome measures
were the Mini Mental State Examination, clock-drawing test, and Trail Making Test A and B.
Results: Changes in the California Verbal Learning Test–Second Edition scores were not significantly different
between the active and placebo stimulation groups for immediate recall (p = 0.270), delayed recall (p = 0.052), or
recognition (p = 0.089). There were nonsignificant differences in score changes on the Mini Mental State Examination
(p = 0.799), clock-drawing test (p = 0.378), and Trail Making Test A (p = 0.288) and B (p = 0.093). Adverse effects
were not observed.
Conclusions: Compared with placebo stimulation, active tDCS stimulation in this clinical trial did not significantly
improve verbal memory function in Alzheimer’s disease. This study differs from previous studies in terms of the
stimulation protocol, trial design, and application of standardized neuropsychological memory assessment.
Trial registration: ClinicalTrials.gov identifier NCT02518412. Registered on 10 August 2015.
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Neuroimaging studies have suggested that Alzheimer’s
disease is associated with pathological and structural
changes in the brain, especially in the temporal cortex
[1]. Several studies have demonstrated that stimulation
of the temporal cortex with transcranial direct current
stimulation (tDCS) can enhance name recall in healthy
elderly persons [2] and improve recognition memory in
patients with Alzheimer’s disease [3–5]. tDCS is non-
invasive and works by inducing a low direct current in
the cortical area of interest [6]. Small electrodes are
placed on the scalp above the brain area that is targeted
by tDCS. This stimulation facilitates cortical excitability
and thereby neuroplasticity [6].
The results of previous studies are promising [3–5].
However, there is still insufficient evidence that supports
tDCS as an intervention for Alzheimer’s disease. Random-
ized, placebo-controlled trials are warranted to assess the
efficacy of temporal cortex tDCS in patients with Alzhei-
mer’s disease. Trials should include more comprehensive
outcome measures to explore the effect of tDCS on mem-
ory function. The aim of the present study was to investi-
gate the effect of tDCS on verbal memory functions in
patients diagnosed with Alzheimer’s disease.
Methods
Study design and participants
A randomized, placebo-controlled trial with a parallel
group design was performed. Two groups were included
in the intervention: an active tDCS group and a placebo
tDCS group. The allocation ratio was 1:1.
Patients diagnosed with Alzheimer’s disease were invited
to participate in the study via a letter from the Department
of Geriatric Medicine at the University Hospital of North
Norway, and healthy participants were recruited through a
newspaper advertisement. The eligibility criteria were living
at home and fulfillment of the research criteria for the
likelihood of having Alzheimer’s disease according to the
revised criteria of the National Institute of Neurological
and Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association criteria [7]. We
followed section 4.2 in these criteria: “Probable Alzheimer’s
disease with increased level of certainty.” This determin-
ation of eligibility for the study requires evidence of a
progressive cognitive decline based on information from
informants (relatives) and a cognitive and/or neuro-
psychological evaluation [7].
We excluded patients who scored <18 on the Mini
Mental State Examination (MMSE) [8]. Other exclusion
criteria included serious somatic disorders (cancer, chronic
obstructive pulmonary disease, and heart failure) or neuro-
psychiatric disorders (e.g., severe depression and psychosis)
that might reduce cognitive abilities. The patients with
comorbid cerebral conditions, such as cerebrovascularinjuries and/or stroke, brain tumor, or Parkinson’s disease,
were not eligible to participate in the study. Patients using
cholinesterase inhibitors had to have been using them for
at least 3 months before enrolling in the study. A total of
25 patients with Alzheimer’s disease were included in the
study.
A total of 22 healthy elderly volunteers, aged 59–83
years, served as controls for the neuropsychological test
performance at baseline. None of them had cognitive
impairment or other serious diseases. These healthy
volunteers were recruited through an advertisement. The
control group did not receive any tDCS stimulation. They
completed the Hospital Anxiety and Depression Scale [9],
a questionnaire used to screen for depression and anxiety.
The neuropsychological test battery used for healthy
volunteers and patients with Alzheimer’s disease was
identical. The study was executed in a research laboratory
at the University of Tromsø Institute of Psychology. The
study was ethically approved by the regional committee
for medical and health research ethics (2012/1890) and
was registered in the ClinicalTrials.gov database with the
identifier NCT02518412. All of the patients and healthy
control subjects signed a written informed consent form
in line with the Declaration of Helsinki before participating
in the study. Each patient received a gift card worth 600
NOK (67 EUR, 75 USD) for their participation. Figure 1
contains a flow diagram of the trial.
Outcome measures
The primary outcome measure was verbal memory function.
We used a validated and standardized Norwegian version of
the California Verbal Learning Test–Second Edition (CVLT-
II) to assess three aspects of verbal memory function: imme-
diate recall, delayed recall, and recognition [10]. CVLT-II is
normed by age and gender and is widely used to assess
patients with Alzheimer’s disease [10]. To reduce test-retest
effects, the CVLT-II consists of two parallel versions: the
CVLT-II standard and alternate forms, which contain two
different and independent word lists. We used the standard
form at baseline and the alternative form in the posttest.
The secondary outcome measures included the MMSE,
clock-drawing test, and Trail Making Test parts A and B
(TMT A and B). The MMSE is a screening tool used for
assessing cognitive impairment (e.g., orientation, recall,
arithmetic, language, and ability to follow simple instruc-
tions) [8]. The clock-drawing test is another screening tool
used for detecting cognitive impairment and is also used
to assess visuoconstructive ability [11]. The TMT consists
of part A and part B. TMT A measures sustained atten-
tion, whereas TMT B assesses executive function [12].
To control for general cognitive abilities, we used the
Wechsler Abbreviated Scale of Intelligence with the
matrix reasoning and vocabulary subtests [13]. To screen
for depressive symptoms, we used the Cornell Scale for
Fig. 1 Flow diagram of trial profile
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completed by an informant (i.e., a relative). A score
above 13 indicates depression, which was an exclusion
criterion in the present study. We documented progres-
sive decline using the Informant Questionnaire on Cog-
nitive Decline in the Elderly (IQCODE) [15], which was
also completed by an informant. To assess for potential
confusion during neuropsychological testing, the Confu-
sion Assessment Method [16] was applied by a research
assistant. This questionnaire is based on the observation
of core symptoms of confusion (e.g., inattention, disor-
ganized thinking, and altered level of consciousness).Intervention
The intervention was treatment with tDCS using a direct
current stimulator (neuroConn, Ilmenau, Germany), which
is battery-driven and delivers a direct current. The current
intensity was 2 mA, and the stimulation duration was
30 minutes. A pair of 35-cm2 rubber electrodes transferred
the direct current. These electrodes were inserted into
sponge pads soaked with 10 ml of sterile water. To stimu-
late the left temporal lobe, the anode (positive electrode)
was placed at the T3 position in the 10–20 system for elec-
troencephalographic electrode positioning. The cathode(negative electrode) was placed on the right frontal lobe at
the Fp2 position. For the placebo tDCS, the electrode
placement and session duration were identical to those for
active tDCS. However, in the placebo tDCS, the current
was delivered for 30 seconds at the beginning of the stimu-
lation, then the current was turned off automatically.Randomization and blinding
The patients were assigned to a list with five-digit codes
provided by the manufacturer of the tDCS stimulator.
Each patient had his or her own code. The codes
instructed the stimulator to deliver either placebo or ac-
tive stimulation. The order of the codes was randomized
using the Random.org website (https://www.random.org/).
To ensure double-blinding, the list of code assignments
was not disclosed during the entire tDCS intervention.
The list was decoded when the study was completed to
identify the patients in the active and placebo groups. The
tDCS stimulator did not display information that could be
used to identify the placebo or active stimulation.Procedure
After their inclusion in the study, the patients and their rel-













Fig. 2 Overview of the procedure
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patient completed an informed consent form. Subse-
quently, the patient underwent neuropsychological testing
(baseline). The neuropsychological assessment lasted for
approximately 60 minutes, including several short breaks.
After the neuropsychological assessment was completed,
the first tDCS stimulation commenced. Each patient under-
went six sessions of tDCS or placebo tDCS stimulation for
10 days. Each tDCS stimulation session lasted 30 minutes.
An experienced research assistant administered the tDCS
stimulation. When the last tDCS stimulation was com-
pleted, the patient performed the neuropsychological post-
testing and received a gift certificate. Figure 2 gives an
overview of the procedure.
Power and statistical analyses
In previous studies in which tDCS was used to stimulate
memory functions in patients with Alzheimer’s disease,Table 1 Baseline characteristics
Active tDCS (n = 12) P
Age, years 70.0 (8.0)70.5 (21.0) 7
Males 7 (58 %) 7
DM 12 (100 %) 1
CVLT-II IR 25 (7.9)22.0 (25.0) 2
CVLT-II DR −2.7 (0.5)−2.5 (2.0) −
CVLT-II RG 0.6 (0.9)0.7 (3.0) 1
TMT A 91.0 (45.0)81.0 (138.0) 1
TMT B 266.0 (123.0)215.0 (266.0) 3
Clock 3.33 (1.4)3.5 (5.0) 1
MMSE 20.0 (2.8)21.0 (8.0) 2
WASI Ma 43.0 (9.2)44.5 (27.0) 4
WASI Vo 41.7 (9.3)39.0 (31.0) 4
Cornell Scale for Depression in Dementia 5.7 (4.3)6.0 (12.0) 4
CAM 0.0 0
IQCODE 3.9 (0.3)4.1 (1.2) 4
DM dementia medications, CVLT-II IR California Verbal Learning Test–Second Edition
Delayed Recall, CVLT-II RG California Verbal Learning Test–Second Edition Recognitio
Questionnaire of Cognitive Decline in the Elderly, CAM Confusion Assessment Meth
transcranial direct current stimulation
Data are the mean (SD) or n (%). Median and range are displayed in italic type. The
groups at baseline. The second p value column displays the differences between th
displayed as age- and gender-adjusted z-scores (normalized mean 0, SD 1). For imm
and for recognition the score is an adjusted d′ score (relationship between total hit
Maximum score on the MMSE is 30. Scores <24 indicate cognitive impairment [8]. S
cutoff score on the IQCODE for Alzheimer’s disease is >3.5 [15]. For the Cornell Scal
ranges from 0 to 4, where 0 indicates no symptoms of confusion. The clock-drawin
ap < 0.05 denotes statistically significant valuesresearchers reported significant results (p < 0.05) with a
total of ≤15 patients [3–5] in a within-group design.
Thus, we aimed to include a larger sample than those
described in previous studies [3–5] to ensure accurate
analysis of the effects of the intervention.
We used IBM SPSS version 22 software (IBM, Armonk,
NY, USA) to perform the statistical analysis. Because of a
violation of the assumption of a normal distribution, a
nonparametric Mann-Whitney U test was conducted to
compare the placebo tDCS and active tDCS groups at
baseline. A nonparametric Kruskal-Wallis test was used to
assess the baseline characteristics for all three groups (pla-
cebo tDCS, active tDCS, and healthy control subjects at
baseline).
For the primary analyses, the data had a normal distri-
bution. However, because of a small sample size and a
large variance, we decided to use a nonparametric Mann-
Whitney U test for the analysis. With the Mann-Whitneylacebo tDCS (n = 13) p Value Controls (n = 22) p Value
5.0 (8.7)75.0 (30.0) 0.12 68.8 (6.8)69.0 (24.0) 0.062
(53 %) 0.85 4 (18 %)
2 (92 %) 0.76
3 (6.8)23.0 (22.0) 1.00 52.7 (10.0)54.0 (33.0) 0.01a
2.3 (0.8)−2.5 (2.5) 0.4 −0.4 (0.9)−0.5 (3.5) 0.01a
.0 (0.5)1.1 (1.8) 0.24 1.5 (1.0)2.4 (3.3) 0.01a
43.0 (65.0)131.0 (191.0) 0.059 48.5 (18.6)46.5 (87.0) 0.01a
47.0 (225.0)259.0 (693.0) 0.67 93.0 (34.8)90.5 (149.0) 0 · 01a
.5 (1.6)1.0 (4.0) 0.024a 4.86 (0.86)5.0 (2.0) 0.01a
1.2 (3.9)23.0 (13.0) 0.71 29.5 (1.09)30.0 (5.0) 0.01a
2.5 (6.9)42.0 (26.0) 0.81 58.05 (9.0)61.5 (34.0) 0.01a
1.6 (14.3)44.0 (48.0) 0.76 57.0 (9.9)57.0 (40.0) 0.01a
.8 (3.4)5.0 (12.0) 0.65
.0 1.0
.1 (0.3)4.2 (1.1) 1 · 0
Immediate Recall, CVLT-II DR California Verbal Learning Test–Second Edition
n, WASI Wechsler Abbreviated Scale of Intelligence, IQCODE Informant
od, MMSE Mini Mental State Examination, TMT Trail Making Test, tDCS
first p value column shows the differences between the placebo and active
e active, placebo, and control groups at baseline. For CVLT-II, delayed recall is
ediate recall the score is displayed as a T-score (normalized mean 50, SD 10),
s and false-positive results). For TMT A and B, results are displayed in seconds.
cores on the WASI are displayed as T-scores (normalized mean 50, SD 10). The
e for Depression in Dementia, a cutoff >12 indicates depression [14]. CAM
g test scores range from 0 to 5, where 5 indicates no errors.
Table 2 Outcome measures
Active tDCS (n = 12) Placebo tDCS (n = 13) Difference p Value
Primary outcomes
CVLT-II immediate recall 5.0 (25.0) 0.0 (31.0) 5.0 0.270
CVLT-II delayed recall 0.0 (1.5) 0.0 (2.5) 0.0 0.052
CVLT-II recognition 0.3 (4.0) −0.08 (1.6) 0.47 0.089
Secondary outcomes
MMSE 1.0 (9.0) 1.0 (10.0) 0.0 0.799
Clock-drawing test 0.0 (4.0) 0.0 (5.0) 0.0 0.378
TMT A 3.5 (262.0) −7.0 (219.0) 10.5 0.288
TMT B 22.0 (204.0) −96.0 (443.0) 118.0 0.093
CVLT-II California Verbal Learning Test–Second Edition, MMSE Mini Mental State Examination, TMT Trail Making Test, tDCS transcranial direct current stimulation
Data are the median (range) values. The median values are the estimated change from baseline to posttesting. The positive values indicate positive changes. For
the CVLT-II immediate recall, the median value is displayed as a T-score. For the CVLT-II delayed recall, the median value is displayed as a scaled z-score. For CVLT
recognition, the median value is an adjusted d′ score. The differences between the placebo and active tDCS were calculated using a nonparametric Mann-Whitney
U test
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The raw scores for the neuropsychological tests (CVLT-II
and WASI) were scaled according to standardized norm
tables [13, 17]. The significance level was set at p < 0.05.
Results
A total of 82 patients diagnosed with Alzheimer’s disease
were assessed for eligibility. Of these patients, 45 were ex-
cluded because of comorbid and serious somatic diseases,
MMSE score <17, and psychiatric diseases. A total of 11
patients declined to participate in the study. One patient
decided to withdraw from the study. Twenty-five patients
were enrolled in the study and completed the intervention
between June 2013 and June 2015. Table 1 shows the pa-
tients’ baseline characteristics.
In our analysis, we found significant differences between
healthy control subjects and patients with Alzheimer’s
disease at baseline. Except for the clock-drawing test, there
were no significant differences in the baseline characteris-
tics between the placebo and active groups (Table 1).
For the primary outcome measures, scores between the
active and the placebo group did not differ significantly
on the CVLT-II immediate recall (95 % confidence inter-
val [CI] −9.00 to 2.00; U = 99.00, z-score = 1.14, p =
0.270, r = 0.22), CVLT-II delayed recall (95 % CI −1.0
to 0.0; U = 113.50, z-score = 2.132, p = 0.052, r = 0.42), orTable 3 Frequency table
Active tDCS (n = 12) Placebo tDCS (n = 13)
CVLT-II immediate recall 9 6
CVLT-II delayed recall 4 1
CVLT-II recognition 7 4
CVLT-II California Verbal Learning Test–Second Edition, tDCS transcranial direct
current stimulation
The data represent the number of patients showing improvement on primary
outcome measures. Improvement was displayed as positive changes from
baseline to posttestCVLT-II recognition (95 % CI −1.25 to 0.18; U =
96.00, z-score = 1.38, p = 0.089, r = 0.27). The scores
on the secondary outcome measures (MMSE, clock-
drawing test, and TMT A and B) did not differ
significantly between the active and placebo tDCS
groups (Table 2). Table 3 display the number of pa-
tients showing improvement on primary outcome
measures.
Safety and tolerability
Both patients and their relatives were told to report likely
adverse effects (e.g., headache, itching, skin irritation).
However, no adverse effects were reported, which
indicates that the tDCS intervention was both safe and
well-tolerated.
Discussion
The aim of the present randomized, placebo-controlled
study was to assess the effect of tDCS stimulation on
verbal memory function in patients with Alzheimer’s
disease. We were unable to reveal significant differences
between the placebo and active tDCS groups in both
primary and secondary efficacy outcomes. We found a
tendency for improved delayed recall in the active tDCS
group, albeit not significant.
Boggio and colleagues stimulated [4] the temporal
cortex in patients with Alzheimer’s disease using a 30-
minute tDCS stimulation for 5 consecutive days. This
stimulation increased visual recognition memory scores
by 8.9 %, and the improvement persisted for 1 month
after the last simulation session.
Our results are not in agreement with the results of
previous studies [3–5], which can be attributed to sev-
eral likely explanations. First, we used a fixed stimulation
protocol for all patients. Several recent studies suggested
that anatomical differences (e.g., skull thickness) can
Bystad et al. Alzheimer's Research & Therapy  (2016) 8:13 Page 6 of 7affect current distributions to the cortex [18]. Future
tDCS studies will likely take advantage of computational
models to ensure individual calibration of the stimula-
tion procedure.
Second, the patients in our study may have been less
receptive to tDCS because of the severity of their
disease. tDCS stimulation seems to be less effective in
the advance stages of Alzheimer’s disease [19, 20].
According to our baseline measures of memory function,
a majority of our patients had severe memory impair-
ment (see CVLT-II characteristics in Table 1). Alzhei-
mer’s disease is associated with reduced neuroplasticity
(i.e., a considerable reduction in long-term potentiation)
[21]. This condition is especially pronounced in the tem-
poral cortex [22] and may inhibit the effect of temporal
cortex stimulation when memory impairment is severe.
Third, our study differs from previous studies [3–5] by
its limited sample size and in terms of the stimulation
procedure, study design, and outcome measures. Ac-
cording to Elder and Taylor [23], different stimulation
paradigms should be investigated in Alzheimer’s disease.
The optimal stimulation procedure for Alzheimer’s is
still uncertain. Thus, the present study is in line with
these recommendations and applied a new stimulation
paradigm. Clinical application of tDCS is still in its in-
fancy [24]. It is important to find the most effective
tDCS paradigm for patients with Alzheimer’s disease.
A major difference between the present study and pre-
vious studies [3–5] is our application of standardized
memory assessment. This accords with recommenda-
tions derived from previous reviews [19, 20]. Neuro-
psychological testing is considered to be the most
reliable method for assessing cognitive function in
Alzheimer’s disease [25]. Furthermore, in the present
study, we applied a randomized, placebo-controlled
design. To the best of our knowledge, this is the first
randomized, placebo-controlled study of tDCS stimula-
tion of the temporal cortex in Alzheimer’s disease.
Additionally, none of our patients experienced any ad-
verse effects due to the intervention, which indicates
that tDCS is safe and well-tolerated.
We recommend future studies with outcome measures
that include neuropsychiatric symptoms, neuropsycho-
logical assessment, and activities of daily living. The
Neuropsychiatric Inventory [26] and the Amsterdam In-
strumental Activities of Daily Living Questionnaire [27]
are recommended in that regard.
Large-scale randomized controlled studies are war-
ranted. Recruitment is a main barrier. Recruitment pre-
sents a challenge for clinical studies of tDCS [18] and
trials in Alzheimer’s disease [28]. One way to facilitate
the recruitment process is to increase the number of
trial sites [28]. In addition, increasing the repetition rate
(e.g., stimulation twice per day) could be more feasibleand might require fewer separate days of visits to the
research laboratory. Such stimulation may even prolong
the aftereffects of stimulation [29, 30]. Fewer visits can
be beneficial for recruitment [28].
Conclusions
This randomized, placebo-controlled study failed to
reveal any significant results. There was a nonsignificant
improvement in delayed recall for the active tDCS
condition. This trial showed high tolerability of tDCS. In
future research, investigators should use both neuro-
psychological and neurophysiological outcome measures,
study patients in early stages of Alzheimer’s disease, and
overcome recruitment barriers to increase power.
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